Comparative guide · 6 min read

Carnitine vs CoQ10 for energy — two mitochondrial supplements compared

Updated 2026-05-17 · Reviewed by SupplementScore editors · No sponsorships

L-carnitine (typically acetyl-L-carnitine in supplement use) and Coenzyme Q10 (usually as ubiquinol) are the two most-asked-about "mitochondrial energy" supplements. Both have legitimate biochemistry — carnitine shuttles long-chain fatty acids into the mitochondria for beta-oxidation; CoQ10 is an electron carrier in the electron transport chain. They have different best-evidenced indications. CoQ10 has the strongest signal in heart failure, statin-associated myopathy, and migraine prevention; ALCAR (acetyl-L-carnitine) has the strongest signal in diabetic peripheral neuropathy, in cognitive decline in older adults, and in chronic fatigue in some subpopulations.

Quick verdict

GoalBetter choiceWhy
Heart failure adjunct (HFrEF)CoQ10 (ubiquinol)Q-SYMBIO trial (2014) showed 43% reduction in major adverse cardiovascular events with 300 mg/day vs placebo.
Statin-associated muscle symptomsCoQ10Modest evidence of myalgia improvement; safe addition for symptomatic statin users.
Migraine preventionCoQ10Multiple RCTs and AHS/AAN guideline mention; 300 mg/day reduces frequency.
Diabetic peripheral neuropathyALCARMeta-analyses show pain reduction and nerve-conduction improvements at 1–3 g/day.
Cognitive symptoms in older adults / mild cognitive impairmentALCARMeta-analyses show small-to-moderate cognitive benefits at 1.5–3 g/day for ≥3 months.
Subjective "low energy" in a healthy adultNeither reliablyMost subjective fatigue traces to sleep, iron, B12, thyroid, mood, or activity — not mitochondrial deficits.

How they actually work

Carnitine — fatty acid shuttle into mitochondria

L-carnitine is a quaternary ammonium compound synthesised from lysine and methionine. It's essential for shuttling long-chain fatty acids across the mitochondrial inner membrane via the carnitine palmitoyltransferase (CPT) system. Acetyl-L-carnitine (ALCAR) is the most-supplemented form because it crosses the blood-brain barrier more efficiently and has the most cognitive and neuropathic-pain data. L-carnitine L-tartrate (LCLT) is the more common sports-recovery form. Plasma carnitine is rarely low in mixed omnivorous diets; vegetarians and vegans have lower stores.

CoQ10 — electron transport chain and antioxidant

CoQ10 (ubiquinone, reduced form ubiquinol) is essential for electron transport between complexes I/II and III, and is a lipid-soluble antioxidant. Statins inhibit HMG-CoA reductase, which sits upstream of CoQ10 synthesis — leading to the rationale for CoQ10 supplementation in statin users. Tissue CoQ10 declines modestly with age. Ubiquinol is the more bioavailable form, particularly in older adults; it's worth the extra cost compared to ubiquinone in most cases.

Heart failure — CoQ10's strongest case

The Q-SYMBIO trial (Mortensen 2014) randomised 420 patients with NYHA III/IV heart failure to CoQ10 100 mg TID or placebo on top of standard therapy. Over 2 years, CoQ10 reduced major adverse cardiovascular events by 43% and all-cause mortality by 42%. The trial was modest in size but the result has been replicated in smaller studies. This is the most clinically meaningful supplement signal in cardiology outside fish oil for hypertriglyceridemia.

Statin-associated muscle symptoms

The mechanistic case for CoQ10 in statin myopathy is plausible (statins lower plasma CoQ10) but trial evidence is mixed. Meta-analyses are inconsistent; some trials show muscle-symptom improvement, others don't. Given the low-harm profile, a 12-week trial at 100–200 mg/day is reasonable in symptomatic patients. ALCAR has no equivalent indication.

Migraine prevention

CoQ10 300 mg/day has multiple RCTs showing reduced migraine frequency over 12 weeks. The American Headache Society and American Academy of Neurology guidelines mention it as a "probably effective" complementary option (Level B/C). Riboflavin 400 mg/day has comparable evidence and pairs well with CoQ10.

Diabetic peripheral neuropathy — ALCAR's strongest case

ALCAR 1–3 g/day for 6–12 months reduces pain and improves nerve conduction in multiple trials of diabetic peripheral neuropathy, including a large multi-center trial by Sima et al. (2005). Effect sizes are modest but meaningful, and the trials are well-conducted. ALCAR has been used as a pharmaceutical in some countries for this indication. CoQ10 has limited neuropathy evidence.

Cognitive symptoms in older adults

ALCAR has multiple trials in mild cognitive impairment, age-related cognitive decline, and (with weaker effect) mild Alzheimer's. Meta-analyses show small-to-moderate effects on cognitive scales. CoQ10 has been trialled in Parkinson's disease — early Phase II showed promise, but the larger Phase III QE3 trial was futile and stopped early. Net: ALCAR has the cognitive case; CoQ10 doesn't.

Subjective "fatigue" — neither is a first-line answer

Adult fatigue most commonly traces to sleep deficit, depression/anxiety, anemia or low ferritin, hypothyroidism, B12 deficiency, sleep apnea, or sedentary deconditioning. CoQ10 and ALCAR have small signals in chronic fatigue syndrome (ME/CFS) and in some cancer-related fatigue studies, but neither is a substitute for working through the basics.

Practical rule. Pick CoQ10 (ubiquinol) for heart failure adjunct, statin-associated myopathy, or migraine prevention. Pick ALCAR for diabetic neuropathy or cognitive symptoms in older adults. For someone with unspecified "low energy" who hasn't worked up sleep, iron, B12, thyroid, and mood — start there before reaching for either.

Dose, form, and timing

CoQ10 (ubiquinol): 100–300 mg/day with a fatty meal for absorption. Heart failure target: 300 mg/day. Migraine target: 300 mg/day. Statin myopathy target: 100–200 mg/day. Ubiquinol is more bioavailable than ubiquinone — worth the premium in older adults.

ALCAR (acetyl-L-carnitine): 1500–3000 mg/day divided BID. Take on an empty stomach or with low-fat meal. L-carnitine L-tartrate (LCLT) 1–2 g/day is the typical sports-recovery form. Some users find ALCAR mildly activating — take earlier in the day.

Safety

CoQ10: well-tolerated. Theoretical interaction with warfarin (vitamin K analog structure); monitor INR. Mild GI upset rare.

L-carnitine/ALCAR: GI upset, fishy body odor at higher doses (TMAO production). Concerns about long-term L-carnitine supplementation and TMAO-mediated atherosclerosis from observational/mechanistic data exist; this is not conclusive in clinical-outcome trials. Discuss with prescriber if on warfarin (mild interaction reported) or thyroid hormone replacement (carnitine can blunt thyroid hormone action at higher doses).

Cost

CoQ10 (ubiquinol 100 mg): $0.40–0.80 per dose. ALCAR (500 mg capsules, 3 g/day): $0.50–1.00 per day. Both are mid-range supplement costs.

Who should pick each

Pick CoQ10 if: you have heart failure with reduced ejection fraction (with cardiologist input), statin-associated muscle symptoms, frequent migraines, or you're an older adult on multiple medications wanting a low-harm mitochondrial adjunct.

Pick ALCAR if: you have diabetic peripheral neuropathy, age-related cognitive complaints, or you're a vegetarian/vegan with lower endogenous carnitine stores wanting a focus/cognition adjunct.

Pick neither (first) if: you have undifferentiated "fatigue" without bloodwork or a sleep evaluation. The yield of a workup is much higher than either supplement.

What we'd actually buy

For a 65-year-old with HFrEF on optimal medical therapy: ubiquinol 100 mg TID for 12+ weeks, alongside standard cardiology care. For a 55-year-old with diabetic peripheral neuropathy on metformin: ALCAR 1 g TID for 6 months, alongside glycemic optimisation. For "I'm tired all the time" without a workup: neither — get bloodwork first.

Sources

Read more: